[go: up one dir, main page]

CY1111857T1 - Κρυσταλλικη βαση trans-1-((1r,3s)-6-xλωpo-3-φαινυλινδαν-1-υλο)-3,3-διμεθυλοπιπεραζινης - Google Patents

Κρυσταλλικη βαση trans-1-((1r,3s)-6-xλωpo-3-φαινυλινδαν-1-υλο)-3,3-διμεθυλοπιπεραζινης

Info

Publication number
CY1111857T1
CY1111857T1 CY20111100928T CY111100928T CY1111857T1 CY 1111857 T1 CY1111857 T1 CY 1111857T1 CY 20111100928 T CY20111100928 T CY 20111100928T CY 111100928 T CY111100928 T CY 111100928T CY 1111857 T1 CY1111857 T1 CY 1111857T1
Authority
CY
Cyprus
Prior art keywords
trans
dimethylpiperazine
hulpo
finylindan
ylo
Prior art date
Application number
CY20111100928T
Other languages
English (en)
Inventor
Benny Bang-Andersen
De Diego Heidi Lopez
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37908539&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111857(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of CY1111857T1 publication Critical patent/CY1111857T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Κρυσταλλική βάση της ένωσης trans-1-((1R,3S)-6-χλωρο-3-φαινυλινδαν-1-υλο)-3,3-διμεθυλοπιπεραζίνης, μέθοδοι για την παρασκευή καθαρισμένης ελεύθερης βάσης ή αλάτων της ένωσης, φαρμακευτικές συνθέσεις που περιλαμβάνουν τη βάση και ιατρική χρήση αυτών, που συμπεριλαμβάνει θεραπεία σχιζοφρένειας και άλλων ψυχωτικών διαταραχών.
CY20111100928T 2005-02-16 2011-09-27 Κρυσταλλικη βαση trans-1-((1r,3s)-6-xλωpo-3-φαινυλινδαν-1-υλο)-3,3-διμεθυλοπιπεραζινης CY1111857T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65341905P 2005-02-16 2005-02-16
DKPA200500239 2005-02-16
EP06706059A EP1853576B1 (en) 2005-02-16 2006-02-14 Crystalline base of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine

Publications (1)

Publication Number Publication Date
CY1111857T1 true CY1111857T1 (el) 2015-11-04

Family

ID=37908539

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100928T CY1111857T1 (el) 2005-02-16 2011-09-27 Κρυσταλλικη βαση trans-1-((1r,3s)-6-xλωpo-3-φαινυλινδαν-1-υλο)-3,3-διμεθυλοπιπεραζινης

Country Status (28)

Country Link
US (2) US7648991B2 (el)
EP (1) EP1853576B1 (el)
JP (1) JP5055135B2 (el)
KR (1) KR101386387B1 (el)
CN (1) CN101119983B (el)
AR (1) AR052909A1 (el)
AT (1) ATE515501T1 (el)
AU (1) AU2006215957B9 (el)
BR (1) BRPI0607436B8 (el)
CA (1) CA2597622C (el)
CY (1) CY1111857T1 (el)
DK (1) DK1853576T3 (el)
EA (1) EA017631B1 (el)
ES (1) ES2368786T3 (el)
HR (1) HRP20110645T1 (el)
IL (1) IL184551A (el)
MX (1) MX2007009980A (el)
MY (1) MY148683A (el)
NO (1) NO339863B1 (el)
NZ (1) NZ556397A (el)
PL (1) PL1853576T3 (el)
PT (1) PT1853576E (el)
RS (1) RS51944B (el)
SI (1) SI1853576T1 (el)
TW (1) TWI376373B (el)
UA (1) UA95901C2 (el)
WO (1) WO2006086986A1 (el)
ZA (1) ZA200705982B (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06001838A (es) 2003-08-18 2006-05-04 Lundbeck & Co As H Sales de succinato y malonato de la trans-4- ((ir, 3s)-6 -cloro-3- fenilindan -1-il)-1, 2, 2- trimetilpiperazina y su uso como medicamento.
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
EP2285377A1 (en) * 2008-05-07 2011-02-23 H. Lundbeck A/S Method for treating cognitive deficits
JP2012504560A (ja) * 2008-10-03 2012-02-23 ハー・ルンドベック・アクチエゼルスカベット 経口製剤
US8575174B2 (en) 2011-06-20 2013-11-05 H. Lundbeck A/S Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia
WO2020089147A1 (en) 2018-10-29 2020-05-07 H. Lundbeck A/S Amorphous compounds of formula (i) and amorphous compounds of formula (i) salts
US11535600B2 (en) 2018-12-03 2022-12-27 H. Lundbeck A/S Prodrugs of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031216A (en) 1974-08-12 1977-06-21 Knoll A.G. Chemische Fabriken 3-(3,4-Dialkoxy-benzyl)-3-methyl-piperazines
NZ196284A (en) 1980-02-29 1983-12-16 Kefalas As 1-piperazino-3-phenylindane derivatives:pharmaceutical compositions
DE3139970A1 (de) 1981-10-08 1983-04-28 Boehringer Mannheim Gmbh, 6800 Mannheim Neue carbonsaeurederivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
US5026853A (en) 1987-04-01 1991-06-25 Janssen Pharmaceutica N.V. 4-substituted-2(or 3)aminocarbonyl-1-piperazineacetamide
US5466806A (en) 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
CZ287406B6 (cs) 1991-11-05 2000-11-15 Smithkline Beecham Corporation Indanové a indenové deriváty, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
CA2091204C (en) 1992-03-11 1997-04-08 Ronald J. Mattson Antiischemic-piperazinyl and piperidinyl-cyclohexanes
DK55192D0 (da) 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
JPH06184132A (ja) 1992-12-22 1994-07-05 Kotobuki Seiyaku Kk ベンゾフラン誘導体及びその製造方法並びに尿酸排泄剤
DK0724552T3 (da) 1993-11-30 1997-12-22 Pfizer Fremgangsmåde til fremstilling af chiralt tetralon
CA2132411A1 (en) 1994-09-19 1996-03-20 Michael Trani Enzymatic esterification of long-chain racemic acids and alcohols
US6410794B1 (en) * 1994-12-16 2002-06-25 Uop Llc Process for preparation of pharmaceutically desired chiral tetralone from tetralones
US6455736B1 (en) * 1994-12-16 2002-09-24 Uop Llc Process for preparation of pharmaceutically desired sertraline and sertraline analogs
US5807897A (en) 1996-03-01 1998-09-15 Zeneca Limited Aminotetralin derivative and compositions and method of use thereof
US6268367B1 (en) 1998-02-23 2001-07-31 Zymogenetics, Inc. Piperazine derivatives for treating bone deficit conditions
EP1073618B1 (en) * 1998-05-01 2003-12-03 Pfizer Products Inc. Process for the production of enantiomerically pure or optically enriched sertraline-tetralone using continuous chromatography
AU769465B2 (en) 1998-05-22 2004-01-29 Scios Inc. Heterocyclic compounds and methods to treat cardiac failure and other disorders
DE19824470A1 (de) 1998-05-30 1999-12-02 Boehringer Ingelheim Pharma Neue Neurokininantagonisten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
GB9818916D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
FR2786769B1 (fr) 1998-12-04 2002-10-25 Synthelabo Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
EP1059302A1 (en) 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Factor VIIa inhibitors
JP2000351773A (ja) 1999-06-08 2000-12-19 Yamanouchi Pharmaceut Co Ltd フラン誘導体からなる医薬
AR031520A1 (es) 1999-06-11 2003-09-24 Vertex Pharma Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
US6369226B1 (en) 1999-06-21 2002-04-09 Agouron Pharmaceuticals, Inc. Substituted benzamide inhibitors of rhinovirus 3C protease
IN187170B (el) * 2000-01-04 2002-02-23 Sun Pharmaceutical Ind Ltd
MXPA06001838A (es) * 2003-08-18 2006-05-04 Lundbeck & Co As H Sales de succinato y malonato de la trans-4- ((ir, 3s)-6 -cloro-3- fenilindan -1-il)-1, 2, 2- trimetilpiperazina y su uso como medicamento.
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
AU2006215956A1 (en) 2005-02-16 2006-08-24 H. Lundbeck A/S Tartrate and malate salts of trans-1-((1R,3S)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法

Also Published As

Publication number Publication date
PL1853576T3 (pl) 2011-12-30
IL184551A0 (en) 2007-10-31
EA017631B1 (ru) 2013-02-28
KR101386387B1 (ko) 2014-04-25
RS51944B (en) 2012-02-29
SI1853576T1 (sl) 2011-11-30
EP1853576A1 (en) 2007-11-14
UA95901C2 (en) 2011-09-26
HK1117525A1 (en) 2009-01-16
BRPI0607436A2 (pt) 2010-04-06
BRPI0607436B8 (pt) 2021-05-25
WO2006086986A1 (en) 2006-08-24
TW200640890A (en) 2006-12-01
HRP20110645T1 (hr) 2011-10-31
ATE515501T1 (de) 2011-07-15
MX2007009980A (es) 2007-09-26
US7648991B2 (en) 2010-01-19
NZ556397A (en) 2010-06-25
CN101119983B (zh) 2014-11-12
AU2006215957A1 (en) 2006-08-24
DK1853576T3 (da) 2011-09-26
CN101119983A (zh) 2008-02-06
CA2597622C (en) 2013-11-12
IL184551A (en) 2014-05-28
KR20070103414A (ko) 2007-10-23
CA2597622A1 (en) 2006-08-24
TWI376373B (en) 2012-11-11
US20080153848A1 (en) 2008-06-26
JP2008530040A (ja) 2008-08-07
BRPI0607436B1 (pt) 2020-10-06
AU2006215957B2 (en) 2011-09-29
ZA200705982B (en) 2009-06-24
NO339863B1 (no) 2017-02-13
ES2368786T3 (es) 2011-11-22
PT1853576E (pt) 2011-09-28
NO20074639L (no) 2007-09-12
EA200701740A1 (ru) 2007-12-28
EP1853576B1 (en) 2011-07-06
AU2006215957B9 (en) 2012-02-16
US20100105699A1 (en) 2010-04-29
US8450324B2 (en) 2013-05-28
AR052909A1 (es) 2007-04-11
JP5055135B2 (ja) 2012-10-24
MY148683A (en) 2013-05-31

Similar Documents

Publication Publication Date Title
CY1111857T1 (el) Κρυσταλλικη βαση trans-1-((1r,3s)-6-xλωpo-3-φαινυλινδαν-1-υλο)-3,3-διμεθυλοπιπεραζινης
CY1113039T1 (el) Ηλεκτρικο και μηλονικο αλας τρανς-4-(1r,3s)-6-χλωρο-3-φαινυλινδαν-1-υλο)-1,2,2-τριμεθυλοπιπεραζινης και η χρηση ως φαρμακο
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
SE0401971D0 (sv) Piperidne derivatives
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
EA200800172A1 (ru) 2,4-диаминопиримидины как ингибиторы aurora
EA200801565A1 (ru) Производные пиримидиниларилмочевины в качестве ингибиторов фактора роста фибробластов ( fgf-фактора )
EA200901373A1 (ru) Аминогетероциклические соединения
CY1112653T1 (el) Κρυσταλλικες τροποποιησεις της πυρακλοστροβινης
CY1109104T1 (el) 1,2,3,4 τετρα-υποκατεστημενη ινδολη για την αντιμετωπιση ασθενειων του αναπνευστικου
UY28473A1 (es) Nuevos compuestos
CY1118179T1 (el) Φαρμακευτικη συνθεση
SE0300480D0 (sv) Novel compounds
EA200701930A1 (ru) Производные пиримидина для лечения гиперпролиферативных нарушений
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
SE0401970D0 (sv) Novel compounds
SE0302139D0 (sv) Novel compounds
GEP20094578B (en) Novel azabicyclic derivatives, preparation method thereof and pharmaceutical compositions containing same
SE0302546D0 (sv) New compounds
SE0402925D0 (sv) Novel Compounds
NO20074593L (no) Tartrat- og malatsalter av trans-1-(6-klor-3-fenylindan-1-yl)-3,3-dimetylpiperazin
BRPI0417858A (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
EA200701856A1 (ru) Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении
CY1109975T1 (el) Παρα-αλκυλ-υποκατεστημενα αμιδια ν-(4-υδροξυ-3-μεθοξυ-βενζυλο) κιναμμωμικου οξεος και η χρησιμοποιηση τους για την παρασκευη φαρμακων